Cargando…
Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI wer...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213031/ https://www.ncbi.nlm.nih.gov/pubmed/25354083 http://dx.doi.org/10.1371/journal.pone.0111477 |
_version_ | 1782341788860678144 |
---|---|
author | Kwan, Marilyn L. Lo, Joan C. Tang, Li Laurent, Cecile A. Roh, Janise M. Chandra, Malini Hahn, Theresa E. Hong, Chi-Chen Sucheston-Campbell, Lara Hershman, Dawn L. Quesenberry, Charles P. Ambrosone, Christine B. Kushi, Lawrence H. Yao, Song |
author_facet | Kwan, Marilyn L. Lo, Joan C. Tang, Li Laurent, Cecile A. Roh, Janise M. Chandra, Malini Hahn, Theresa E. Hong, Chi-Chen Sucheston-Campbell, Lara Hershman, Dawn L. Quesenberry, Charles P. Ambrosone, Christine B. Kushi, Lawrence H. Yao, Song |
author_sort | Kwan, Marilyn L. |
collection | PubMed |
description | A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p<0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures. |
format | Online Article Text |
id | pubmed-4213031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42130312014-11-05 Bone Health History in Breast Cancer Patients on Aromatase Inhibitors Kwan, Marilyn L. Lo, Joan C. Tang, Li Laurent, Cecile A. Roh, Janise M. Chandra, Malini Hahn, Theresa E. Hong, Chi-Chen Sucheston-Campbell, Lara Hershman, Dawn L. Quesenberry, Charles P. Ambrosone, Christine B. Kushi, Lawrence H. Yao, Song PLoS One Research Article A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157 invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture. Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p<0.0001). Among initial AI users, the associations of history of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced fractures. Public Library of Science 2014-10-29 /pmc/articles/PMC4213031/ /pubmed/25354083 http://dx.doi.org/10.1371/journal.pone.0111477 Text en © 2014 Kwan et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Kwan, Marilyn L. Lo, Joan C. Tang, Li Laurent, Cecile A. Roh, Janise M. Chandra, Malini Hahn, Theresa E. Hong, Chi-Chen Sucheston-Campbell, Lara Hershman, Dawn L. Quesenberry, Charles P. Ambrosone, Christine B. Kushi, Lawrence H. Yao, Song Bone Health History in Breast Cancer Patients on Aromatase Inhibitors |
title | Bone Health History in Breast Cancer Patients on Aromatase Inhibitors |
title_full | Bone Health History in Breast Cancer Patients on Aromatase Inhibitors |
title_fullStr | Bone Health History in Breast Cancer Patients on Aromatase Inhibitors |
title_full_unstemmed | Bone Health History in Breast Cancer Patients on Aromatase Inhibitors |
title_short | Bone Health History in Breast Cancer Patients on Aromatase Inhibitors |
title_sort | bone health history in breast cancer patients on aromatase inhibitors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213031/ https://www.ncbi.nlm.nih.gov/pubmed/25354083 http://dx.doi.org/10.1371/journal.pone.0111477 |
work_keys_str_mv | AT kwanmarilynl bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT lojoanc bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT tangli bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT laurentcecilea bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT rohjanisem bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT chandramalini bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT hahntheresae bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT hongchichen bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT suchestoncampbelllara bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT hershmandawnl bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT quesenberrycharlesp bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT ambrosonechristineb bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT kushilawrenceh bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors AT yaosong bonehealthhistoryinbreastcancerpatientsonaromataseinhibitors |